| http://www.w3.org/ns/prov#value | - Nevertheless, recent data from a phase I clinical trial suggests that administration of neutralizing monoclonal antibodies against IFN?? can ameliorate disease activity [97].The foregoing evidence clearly implicates TNF in the accelerated atherogenesis and other cardiovascular events associated with autoimmune diseases such as rheumatoid arthritis (RA) and SLE. Several TNF antagonists are currentl
|
